Content
Frontiers of Medicine >> 2020, Volume 14, Issue 6 doi: 10.1007/s11684-020-0740-6
Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma
. Department of Hematology, Tongji Hospital of Tongji University School of Medicine, Shanghai 200065, China.. Department of Imaging, Tongji Hospital of Tongji University School of Medicine, Shanghai 200065, China.. Clinical Translational Research Center, Shanghai Pulmonary Hospital of Tongji University School of Medicine, Shanghai 200433, China
Abstract
Keywords
anti-CD19 chimeric antigen receptor T cells ; mantle cell lymphoma ; relapsed or refractory ; long-term follow-up
Content